The US Food and Drug Administration (FDA) has approved Sanofi’s Merilog (insulin-aspart-szjj), a biosimilar to Novolog ...
Sanofi’s type 2 diabetes combination drug Suliqua has been approved in Europe – setting the scene for a showdown with Novo Nordisk’s rival, Xultophy. The EU approval means Sanofi and Novo ...
The FDA has approved Merilog (insulin-aspart-szjj), a biosimilar to Novolog (insulin aspart), for improving glycemic control ...
The U.S. Food and Drug Administration approved Merilog as biosimilar to Novolog for the improvement of glycemic control in adults and pediatric patients with diabetes mellitus. “Merilog ...
Merilog’s approval comes as the insulin space has over the past year suffered several setbacks, including strong calls for price caps and, potentially, the rise of the mammoth GLP-1 market.
Sanofi is closer to selling a 50% controlling stake in the consumer health business, Opella to private equity Clayton ...
Sanofi’s cardiovascular (CV) and central nervous system (CNS) therapies have gained traction, supported by partnerships.
Sanofi India's board has recommended a final dividend of ₹117 per equity share of ₹10 face value, subject to shareholder ...
Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback